|
|
|
| Webinar: Optimize Your Process For Producing High-Concentration Drugs | The number of high-concentration monoclonal antibodies (mABs) is expected to grow 13% annually from 2024 to 2029. This growth presents challenges in drug manufacturing, such as maximizing product recovery and managing viscosity and protein aggregation. This webinar will discuss solutions for these challenges, including process development, optimizing concentration, and strategies for improving product recovery and streamlining production methods. Click here to learn more. |
|
|
FOCUS ON DOWNSTREAM MANUFACTURING |
|
|
|
By Julian Galbusera, Ines Zimmermann, and Paula Fraga-García, Technical University of Munich | A technique used widely in other industries like steel production and wastewater treatment has emerged as rising star within bioprocessing over the last 10 to 15 years. | |
|
|
|
|
| Optimize mAb Purification Using Protein A Membrane Chromatography | Poster | By M. Marinova, A.C. Lyons, M. DeVore, S. Madasu, M.C. Kerzic, and C.A. Mitchell, W.L. Gore & Associates | Discover how high throughput (HTP) screening can utilize membrane chromatography at comparable consumables costs to traditional resins without compromising CQAs for prescribed therapeutics. |
|
|
| Solvent-Free Purification Of D84-mer Oligonucleotide | Poster | Cytiva | Capto PlasmidSelect and Capto Q ImpRes resins enable this solvent-free process with high-purity, scalable purification of long oligonucleotides, achieving more than 95% of full-length product purity. |
|
|
| 4 Questions To Ask Your Fill/Finish Partner | Article | By Ramon Gonzalez, Ajinomoto Bio-Pharma Services | Reducing risk while maximizing API volume is critical during the fill/finish phase of biopharmaceutical manufacturing. To ensure safety and quality, partner with an experienced fill finish provider. |
|
|
DOWNSTREAM MANUFACTURING SOLUTIONS |
|
|
|
|
|
|
|
|
|
| The debate rages on. While the automation that enables continuous processing gets a lot of hype, there are plenty of dyed-in-the-wool biopharma pros who contend that process optimization and intensification yield comparable benefits, without requiring the capital-intensive process overhaul that continuous demands. Join Bioprocess Online Live for a virtual deep dive into the scalability, sustainability, and capital implications of the continuous-versus-optimized debate. Registration is free thanks to the support of Cytiva. |
|
|
|
| Understanding Injectable Drug Container Closure Systems | Article | By Louis Brasten, West Pharmaceutical Services, Inc. | Choosing the right container closure system (CCS) format is crucial, so understanding the different parts involved, their functions, storage requirements, and how they impact administering the drug is essential. |
|
|
| An Industry-Backed Approach To Container Closure Integrity | Article | By Fred Bathke and Jean Sebastien Steffen, Lonza | Ensuring container closure integrity in an increasingly complex pharmaceutical industry requires a holistic approach that incorporates quality control into all phases of product design and development. |
|
|
|
|
|
| Connect With Bioprocess Online: |
|
|
|
